Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Unknown Analyst

All right. Good morning, everyone. Thanks for being here on day 2 of the Morgan Stanley Global Healthcare Conference. We’re very excited to have the team from Kymera here for this session. Let me just get a quick disclosure out of the way. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.

All right. So with that, welcome, guys. And earlier this year, you celebrated your 10-year anniversary as a company. You’re approaching another set of milestones now. So before we dive in, can we maybe give the audience a bit of an intro on the company and your degrader programs?

Nello Mainolfi
Co-Founder, President, CEO & Director

Yes. So first of all, thanks for having us. So yes, the idea when we started Kymera in May of 2016 was there is tons of biological data tying disease-causing protein to diseases. And we’ve really lacked the right technology to address many of them. And while we make so much progress with oligo-based therapeutics and obviously, injectable biologics and traditional small molecules, there was still a big gap. And I would argue there’s still a big gap.

Only, I think, 20%, 25% of the proteome has been drugged. And so we saw this new small molecule-based modality called targeted protein degradation as a means to expand the number of targets we can go after and ideally, obviously, fulfill some of the key unmet needs that are still out there. And so as people that might have heard about protein degradation is this modality that uses the ubiquitin-proteasome system, which is the cellular machinery responsible for protein homeostasis and directs against